The Food and Drugs Authority (FDA) has paid a courtesy call on the World Health Organization (WHO) Ghana Country Office, led by the Acting Chief Executive Officer, Prof. Kwabena Frimpong-Manso Opuni. The visit underscored the FDA’s commitment to deepening strategic partnerships that enhance public health outcomes both locally and across Africa.

During the meeting, discussions focused on critical areas including regulatory systems strengthening, vaccine safety, laboratory capacity enhancement, and technical support for National Regulatory Authorities. These collaborations are intended to ensure that regulatory frameworks are robust, evidence-based, and capable of addressing emerging health challenges.

The FDA and WHO also explored opportunities to support local pharmaceutical manufacturing in Ghana, particularly initiatives aimed at achieving WHO prequalification. Such efforts are expected to enhance the quality, safety, and efficacy of locally produced health products, while also fostering sustainable regulatory practices.

“Our partnership with the WHO remains central to our mission of protecting public health. By strengthening regulatory systems and supporting local manufacturing, we are creating a healthier and safer future for Ghanaians,” said Prof. Kwabena Frimpong-Manso Opuni, Acting CEO of the FDA.

Through sustained engagement and collaboration with WHO, the FDA reaffirms its dedication to building resilient regulatory systems, promoting public health, and safeguarding the well-being of Ghanaians and populations across the African continent.